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p53 is known to repress transcription of a number of
genes, but the mechanism of p53 recruitment to these
target genes is unknown. The c-myb proto-oncogene
product (c-Myb) positively regulates proliferation of im-
mature hematopoietic cells, whereas p53 blocks cell cy-
cle progression. Here, we demonstrate that p53 inhibits
c-Myb-induced transcription and transformation by di-
rectly binding to c-Myb. The ability of c-Myb to maintain
the undifferentiated state of M1 cells was also sup-
pressed by p53. p53 did not affect the ability of c-Myb to
bind to DNA but formed a ternary complex with the
corepressor mSin3A and c-Myb. Thus, p53 antagonizes
c-Myb by recruiting mSin3A to down-regulate specific
Myb target genes.
The product of the TP53 tumor suppressor gene, p53, moni-
tors the cellular response to various stresses, including geno-
toxic damage. In response to these stimuli, p53 becomes post-
translationally stabilized and activated as a transcription
factor (for review see Refs. 1–3). The cellular outcomes of this
response are cell cycle arrest at the G1 or G2/M checkpoints
and/or induction of apoptosis. This is related to its function as
a sequence-specific transcription factor for the induction of a
group of target genes, including p21waf1/cip1 (4). The consensus
p53-binding element has been found in many promoters that
are activated by p53. Transcriptional mediators, including the
histone acetyltransferase p300/CBP, and arginine methyl-
transferases, PRMT1 and CARM1, have critical roles in p53-
dependent transcriptional activation (5).
Conversely, p53 has been shown to repress a variety of
cellular promoters. The genes found to be negatively regulated
following p53 induction includeMap4, DNA topoisomerase II,
presenilin-1, bcl-2, and others (6–9). Certain human tumor-
derived mutant forms of p53 are defective at trans-repression
but not trans-activation (10). Deletion of the proline-rich region
of p53 renders it defective at apoptosis induction and trans-
repression, but not trans-activation (11, 12). Thus, transcrip-
tional repression by p53 plays an important role in p53-depend-
ent growth control. The interaction of p53 with the corepressor
mSin3A is required for p53 to repress transcription (13). How-
ever, no consensus-binding element of p53 has been clearly
identified in most of the p53-repressible promoters. Thus, the
mechanism by which p53 is recruited to these target genes
remains unknown; one possibility, addressed in this report, is
that p53 interacts with other transcription factors bound to
p53-repressed promoters.
The expression level of the c-myb proto-oncogene is high in
immature hematopoietic cells, and its expression is turned off
during differentiation (14). Similarly, the c-myb mRNA level is
down-regulated during IL-6 1-induced differentiation of M1
myeloblastic cells into macrophages, whereas constitutive ex-
pression of exogenous c-myb blocks this differentiation (15). A
study of c-myb-deficient mice indicated that c-myb is essential
for proliferation of immature hematopoietic cells (16), and anal-
ysis of tissue-specific c-mybKOmice revealed that c-myb is also
required for T cell development at several stages (17).
The c-myb gene product (c-Myb) binds to a specific DNA
sequence and regulates transcription (18–21). Various target
genes of c-Myb, including c-myc, are involved in cell cycle
control and blockage of apoptosis (22–25). In addition, c-Myb
activates the chaperone gene promoters by interacting with
heat shock transcription factor 3 without directly binding to the
promoter itself (26). c-Myb has three functional domains that
are responsible for DNA binding, transcriptional activation,
and negative regulation (19). The DNA-binding domain (DBD)
of c-Myb consists of three imperfect tandem repeats of 51–52
amino acids, each containing a variant helix-turn-helix motif
(27). The transcriptional co-activator CBP binds to the c-Myb
transcriptional activation domain (28). Deletion of the negative
regulatory domain increases both trans-activation and trans-
formation capability, implying that the negative regulatory
domain normally represses c-Myb activity (19, 29–31). Re-
cently, we reported that multiple corepressors, including Ski
and mSin3A, bind directly to the DBD and the negative regu-
latory domain of c-Myb, and inhibit c-Myb-dependent trans-
activation (32).
In this study we demonstrate that p53 directly interacts with
c-Myb bound to promoters of certain Myb target genes, and
inhibits c-Myb-induced transcription of these genes by recruit-
ing mSin3A. Thus, c-Myb-p53 interaction is critical in the
selection of the target genes to be repressed.
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EXPERIMENTAL PROCEDURES
In Vitro Binding Assay—GST pull-down assays were performed as
described previously (33). Binding buffer consisted of 20 mM Hepes (pH
7.5), 01% Nonidet P-40, 1 mM EDTA, 5 mM dithiothreitol, 150 mM NaCl.
Sumoylated GST-p53 was prepared as follows. His-tagged Aos1-Uba2
fusion protein (34), His-tagged Ubc9, GST-SUMO-1, and GST-SUMO-2
were expressed in Escherichia coli and purified. Aos-Uba2 (0.2 M),
Ubc9 (3 M), SUMO-1 or SUMO-2 (20 M), and GST-p53 (10 M) were
incubated in the sumoylation buffer (25 mM Hepes, pH 7.5, 50 mM KCl,
1 mM dithiothreitol, 4 mM MgCl2, 0.05% Triton X-100, 5 mM ATP, 5%
glycerol) at 30 °C for 4 h.
Co-immunoprecipitation Assay—To study the interaction between
c-Myb and p53, 293T cells were transfected with a mixture of the c-Myb
expression plasmid, pact-c-Myb (3 g), and the p53 expression plasmid,
pact-p53 (0.5 g). Forty hours after transfection, cell lysates were
prepared in lysis buffer A (50 mM Hepes (pH 7.5), 250 mM NaCl, 0.2 mM
EDTA, 10 M NaF, 0.5% Nonidet P-40). After reducing the final NaCl
concentration to 150 mM by adding lysis buffer A, which lacks NaCl,
immunoprecipitation was performed with rabbit antibody raised
against GST-p53, and the immunocomplexes were subjected to Western
blotting with an anti-Myb monoclonal antibody 1.1. For co-immunopre-
cipitation of endogenous c-Myb and p53, lysates were prepared from
Molt-4 cells by mild sonication in LSLD buffer (50 mM Hepes, pH 7.4, 50
mM NaCl, 0.1% Tween 20, 20% glycerol), and immunoprecipitated with
the rabbit antibody against GST-p53. The immunocomplexes were then
analyzed by Western blotting with anti-Myb 1.1.
For two-step co-immunoprecipitation, 293T cells were transfected
with a mixture of the FLAG-c-Myb expression plasmid pact-FLAG-c-
Myb (3 g) and the p53 expression plasmid pact-p53 (0.5 g). For first
immunoprecipitation controls, the pact-c-Myb plasmid, which expresses
untagged c-Myb was used. Forty hours after transfection, cell lysates
were prepared using lysis buffer A. After reducing the final NaCl
concentration to 150 mM, the lysates were incubated with anti-FLAG
M2-agarose (Sigma), and the beads were washed with lysis buffer A
containing 150 mM NaCl. The FLAG-linked complexes were eluted with
lysis buffer A containing 150 mM NaCl and 3 FLAG peptide (100
g/ml). After decreasing the concentration of 3 FLAG peptide to 25
g/ml by adding lysis buffer A containing 150 mM NaCl, anti-p53
monoclonal antibodies (DO-1, Santa Cruz Biotechnology) or control IgG
were used for second immunoprecipitation.
Luciferase Reporter Assays—Using the LipofectAMINE Plus reagent
(Invitrogen), 293T or HepG2 cells were co-transfected with a mixture of
the 6MBS-Luc reporter (0.2 g), the c-Myb expression plasmid
pcDNA3-c-Myb (0.1 g), the p53 expression plasmid pcDNA3-p53 (0.1,
0.3, or 1.0 g), and internal control plasmid pRL-TK (Invitrogen) (0.05
g). Cells were also transfected with the c-myc-Luc reporter (0.2 g)
together with the c-Myb expression plasmid (1 g), the p53 expression
plasmid (0.1, 0.3, or 1.0 g), and internal control plasmid pRL-TK (0.05
g). The amount of total DNA was adjusted to 2.0 g with the control
empty vector. In the experiments shown in Fig. 2C, transfected cells
were treated with adriamycin (Sigma) at 0.1, 0.5, or 1.0 g/ml for 24 h
before the luciferase assays. Forty hours after transfection, the cells
were lysed, and luciferase activities were analyzed using the dual-
luciferase assay system (Promega).
Transformation and Analysis of M1 Cell Clones—Fetal liver cells
were isolated from E14.5 embryos, which were obtained by mating
p53/ males and females (35). Transformation assays using fetal liver
cells and the retroviruses encoding various forms of Myb were per-
formed as described previously (36).
M1 cells were grown in Dulbecco’s modified Eagle’s medium contain-
ing 10% fetal bovine serum. The retroviral vectors for c-Myb and p53ts
were constructed using the murine stem cell virus-based retroviral
vector, and M1 cell clones expressing c-Myb together with neomycin-
resistance gene were isolated as described (32). Several independent
clones were isolated, and their level of c-Myb expression was measured.
Using the M1 cell clones containing c-myb virus, cell pools expressing
the p53ts mutant were isolated by selecting the enhanced green fluo-
rescence protein-positive cells. M1 cell clones were induced to differen-
tiate with IL-6 (50 ng/ml, Wako) after seeding at a concentration of 1 
105 cells/ml for 72 h at 32 °C. Cells were stained with a phycoerythrin-
conjugated anti-mouse CD14 monoclonal antibody (BD Pharmingen) on
ice for 30 min after blocking with 3% fetal bovine serum and analyzed
on a FACSCalibur flow cytometer (BD Biosciences).
DNAMicroarrays—RNAwas prepared from various types of M1 cells
using TRIzol reagent (Invitrogen), and biotin-labeled RNA for Gene-
Chip analysis was then prepared according to the protocol, which is
available on the Affymetrix web site. The Mouse Genome Array that
contains 39,000 transcripts (Affymetrix, 430 2.0) was used for the
analysis.
Gel Retardation Assays and Chromatin Immunoprecipitation As-
say—Gel retardation assays were performed using a double-stranded
oligonucleotide probe containing Myb binding site-I as described before
(37). Proteins and antibodies were preincubated on ice for 4 h before
initiation of the DNA binding reaction. Complexes were analyzed on 8%
polyacrylamide gels. ChIP assay was carried out as described before
(32).
RESULTS
Direct Interaction of c-Myb with p53—We previously demon-
strated that p53 binds to heat shock transcription factor 3 and
inhibits c-Myb-induced heat shock transcription factor 3 acti-
vation (33). During analysis of the interactions between p53,
c-Myb, and heat shock transcription factor 3, we have found
that p53 also directly binds to c-Myb. To further examine the
interaction between c-Myb and p53, we performed GST pull-
down assays using various forms of in vitro translated c-Myb
and GST-p53 fusion proteins. The results indicate that the
region containing repeats 2 and 3 in the DBD of c-Myb bind to
GST-p53 (Fig. 1A and supplemental Fig. S1). The three hydro-
phobic amino acids on the surface of repeat 2 of c-Myb DBD,
which are mutated into non-hydrophobic amino acids in the
v-Myb encoded by avian myeloblastosis virus, are involved in
interactions with various proteins, including C/EBP and co-
repressors such as Ski (38, 32). However, the mutant R23
fragment of c-Myb (R23–3M), in which these amino acids are
changed to the same non-hydrophobic amino acids found in
v-Myb, efficiently bound to GST-p53 (Fig. 1A), as did the bac-
terially expressed R123 fragment of c-Myb (Fig. 1A). Thus, p53
directly binds to the DBD of c-Myb.
To identify the regions of p53 that interact with c-Myb, we
used various forms of in vitro translated p53 in pull-down
assays with GST-c-Myb. The results indicate that the C-termi-
nal 78-amino acid region, which contains the tetramerization
domain, is responsible for the interaction with c-Myb (Fig. 1B
and supplemental Fig. S2). To investigate complex formation
between c-Myb and p53 in vivo, co-immunoprecipitation exper-
iments were performed. Lysates were prepared from 293T cells
co-transfected with c-Myb and p53 expression plasmids and
precipitated with anti-p53 antibody, after which the immuno-
complex was subjected to Western blotting with anti-c-Myb
antibody. Fig. 1C shows that c-Myb was co-precipitated by the
anti-p53 antibody, but not the control IgG. We also performed
co-immunoprecipitation of endogenous proteins in Molt-4 cell
lysates, where again we found that anti-p53 antibody co-pre-
cipitated c-Myb, whereas normal IgG did not (Fig. 1D).
p53 Inhibits c-Myb-dependent trans-Activation—To deter-
mine whether p53 can affect c-Myb-induced trans-activation,
we performed luciferase reporter assays using a reporter con-
struct containing the Myb-binding sites (6MBS-Luci). Trans-
fection of 293T cells or HepG2 cells with 6MBS-Luci, c-Myb
expression vector and increasing amounts of p53 expression
vector indicated that p53 suppressed c-Myb-induced trans-ac-
tivation in a dose-dependent manner in both cell types (Fig. 2,
A and B). Adriamycin treatment, which induces p53 protein
expression, also inhibited c-Myb-induced luciferase expression
from the 6MBS-Luci reporter in a dose-dependent manner
(Fig. 2C).
We next investigated the effect of p53 on c-Myb-dependent
trans-activation of the promoter of a known c-Myb target gene,
c-myc. Using a c-myc promoter-containing luciferase reporter
(c-myc-Luci) it was found that p53 did suppress c-Myb-depend-
ent transcription from this promoter (Fig. 2D). To investigate
whether p53 also inhibits the activity of oncogenically activated
forms of Myb, we used v-Myb, 3M, and CT3 in the luciferase
reporter assays. v-Myb is encoded by avian myeloblastosis vi-
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rus, whereas CT3 is a C-terminally truncated form of c-Myb;
both of these forms of Myb have a strong transforming capacity.
In the 3M mutant, the three hydrophobic amino acids in repeat
2 of the DBD have been replaced with non-hydrophobic amino
acids, analogous to the avian myeloblastosis virus-encoded v-
Myb. p53 inhibited c-myc promoter activity induced by all three
forms of Myb (Fig. 2E), suggesting that oncogenic activation of
c-myb is not due to the abrogation of negative regulation of
c-Myb activity by p53.
p53 Inhibits c-Myb Capacity to Control Cellular Prolifera-
tion—We next asked whether p53 plays a biological role as a
negative regulator of c-Myb. To address this, we first examined
the effect of p53 on the transforming capacity of Myb. Trans-
forming recombinant retroviruses that express full-length
wild-type c-Myb or the oncogenically activated C-truncated
form CT3 were generated (36), and the capacity of these viruses
to transform fetal liver cells prepared from wild-type, p53/,
or p53/ mice was compared. Loss of p53 enhanced transfor-
FIG. 1. p53 directly binds to c-Myb.
A, p53 binds to the DBD of c-Myb. Upper
panel, the domain structure of c-Myb and
various forms of c-Myb used are shown.
The results of binding assays are summa-
rized on the right. Lower left panel, GST
fusion protein containing full-length p53
was analyzed by SDS-PAGE followed by
Coomassie Blue staining. Lower middle
panel, binding of two forms of in vitro
translated c-Myb to GST-p53 resin was
analyzed by SDS-PAGE followed by auto-
radiography. Lower right panel, GST pull-
down assays were performed using GST-
p53 and the bacterially expressed
recombinant c-Myb containing three re-
peats of the c-Myb DBD (R123). B, c-Myb
binds to the C-terminal region of p53. Up-
per panel, the domain structure of p53
and the three forms of p53 used are
shown. The results of binding assays are
summarized on the right. Lower left
panel, GST-c-Myb fusion proteins were
analyzed by SDS-PAGE followed by Coo-
massie Blue staining. The arrow indicates
the full-length GST-c-Myb. Lower middle
and right panels, binding of three forms of
in vitro translated p53 to GST-c-Myb was
examined. C, co-immunoprecipitation of
overexpressed c-Myb and p53. Lysates
from 293T cells transfected with the plas-
mid encoding c-Myb and p53 were precip-
itated with the antibody shown above,
and the immunocomplexes were analyzed
by Western blotting with anti-c-Myb an-
tibody. The left-most lanes contain sam-
ples of the whole cell lysates. D, co-immu-
noprecipitation of endogenous proteins.
Lysates from Molt-4 cells were precipi-
tated with the antibody shown above, and
the immunocomplexes were analyzed by
Western blotting with anti-c-Myb
antibody.
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mation by these viruses in a dose-dependent manner (Fig. 3A),
demonstrating that p53 does suppress the transforming capac-
ity of Myb.
One element of the ability of Myb to transform hematopoietic
cells is its capacity to suppress differentiation. We therefore
next investigated the effect of overexpressing p53 on the capac-
ity of c-Myb to maintain the undifferentiated state of M1 mye-
loblastic leukemia cells, which lack functional endogenous p53.
Upon IL-6 stimulation, M1 cells undergo terminal differentia-
tion into macrophage-like cells. However, constitutive expres-
sion of c-Myb in M1 cells blocks this IL-6-induced differentia-
tion (15). We generated M1 cell clones that constitutively
express c-Myb alone, or both c-Myb and the temperature-sen-
sitive mutant of p53 (p53ts), as well as control clones contain-
FIG. 2. Negative regulation of the
trans-activating capacity of c-Myb by
p53. A and B, p53 inhibits c-Myb-depend-
ent transcription from the Myb sites-con-
taining promoter. 293T (A) or HepG2 (B)
cells were transfected with a luciferase
reporter containing six Myb-binding sites
(6MBS-Luci) with () or without () the
c-Myb expression plasmid and increasing
amounts of the p53 expression plasmid.
Luciferase activity was then measured.
The relative level of luciferase activity is
indicated. The average of three experi-
ments is shown ( S.D.). C, adriamycin
inhibits c-Myb-dependent transcription
from the Myb sites-containing promoter.
293T cells were transfected with the
6MBS-Luci reporter with () or without
() the c-Myb expression plasmid, and
then cells were treated with various con-
centrations of adriamycin. Luciferase ac-
tivity was measured, and the results
shown are average  S.D. D, p53 inhibits
the c-Myb-induced activation of the c-myc
promoter. HepG2 cells were transfected
with the luciferase reporter containing
the c-myc promoter (c-myc-Luci) with ()
or without () the c-Myb expression plas-
mid and increasing amounts of the p53
expression plasmid. E, p53 inhibits the
trans-activating capacity of the oncogeni-
cally activated forms of c-Myb. Luciferase
reporter assays were performed as de-
scribed in D except that the plasmids ex-
pressing three forms of c-Myb, as shown
above, were used.
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ing the empty vector (Fig. 3B). This p53ts mutant (Val-135
mutant) behaves like other p53 mutants at 37 °C, but like
wild-type p53 at 32 °C (39). IL-6 treatment caused the control
M1 cells to differentiate into macrophages and express the cell
surface differentiation marker CD14 (Fig. 3C, left). In contrast,
the cells constitutively expressing c-Myb did not efficiently
express CD14 when IL-6 was added (Fig. 3C, middle). When
p53 was overexpressed in the Myb-expressing cells at 32 °C,
differentiation was induced in response to IL-6, resulting in
increased CD14 positivity (Fig. 3C, right), whereas induction of
differentiation was not observed at 37 °C (data not shown).
Thus, p53 induces M1 cell differentiation by inhibiting
c-Myb activity.
p53 Down-regulates Multiple c-Myb Target Genes—To inves-
FIG. 3. p53 inhibits the ability of c-
Myb to enhance cellular prolifera-
tion. A, p53 suppresses the Myb-induced
transformation of fetal liver cells. Fetal
liver cells were prepared from the wild-
type, p53/, and p53/ mice, and in-
fected with retroviruses that express full-
length c-Myb, oncogenically active CT3,
or no protein. The average number of col-
onies formed in three experiments are in-
dicated ( S.D.). p values are also shown.
N.S., no significant difference. Note that
full-length c-Myb can transform fetal
liver cells depending on the cell density
(36) and that under the condition used
here full-length c-Myb also has a trans-
forming capacity. B and C, p53 blocks the
ability of c-Myb to maintain the undiffer-
entiated state of M1 cells. M1 cell clones
infected with either the retrovirus vector
that expresses c-Myb and a neomycin-re-
sistant marker, or p53ts and an enhanced
green fluorescence protein marker were
isolated, and the expression of c-Myb or
p53 in typical clones was analyzed by
Western blotting (B). M1 cell clones that
constitutively express c-Myb with or with-
out p53ts were treated with IL-6 or the
control solvent and CD14 expression was
examined by flow cytometry (C). Note
that the CD14 expression level after IL-6
treatment was lower than previously pub-
lished data due to cultivation at 32 °C.
FIG. 4. p53 down-regulates a significant number of the c-Myb target genes. RNAs were prepared from the control M1 cells and M1 cells
that constitutively express c-Myb, both of which had been treated with IL-6 at 32 °C. The cDNA probes prepared from these RNAs were then used
for DNA array analysis. The expression levels of 122 genes were more than 10-fold higher in the c-Myb-expressing cells than in the control cells.
RNAs were also prepared from the IL-6-treated M1 cells, which constitutively express c-Myb with or without p53ts, and DNA array analysis was
performed. The expression levels of 642 genes were more than 2-fold lower in the p53-expressing cells relative to the control cells. Comparison of
these 642 genes with the 122 genes up-regulated in c-Myb-expressing cells identified 28 genes in common, indicating that these 28 genes are up-
and down-regulated by c-Myb and p53, respectively. These 28 genes are indicated on the right. Dio2, iodothyronine deiodinase type II; Nphp1,
nephronophthisis 1 (juvenile), Pol, DNA polymerase , Atp6ip1, H transporting ATPase lysosomal interacting protein 1; Flt3, FMS-like tyrosine
kinase 3, Skp2, S-phase kinase-associated protein 2 (p45); MEF2C, myocyte enhancer factor 2. The degrees of activation and repression of c-myc
by c-Myb and p53, respectively, are also shown.
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tigate whether p53 induction leads to suppression of c-Myb
target genes, including c-myc, we determined by DNA array
analysis how many and which c-Myb-induced genes are regu-
lated by p53. RNAs were prepared from the M1 cells constitu-
tively expressing c-Myb and from control M1 cells, which were
treated with IL-6 for 2 days and subjected to DNA array anal-
ysis with the Affymetrix Mouse Genome Array 430 2.0, which
represents 39,000 transcripts. Because IL-6 treatment leads to
down-regulation of endogenous c-myb mRNA, the expression
level of c-Myb target genes should be lower in the control M1
cells, relative to the c-Myb-expressing cells. The results indi-
cate that 533 genes are up-regulated more than 5-fold in the
c-Myb-expressing cells compared with the control M1 cells
(data not shown), and among these, 122 genes were up-regu-
lated more than 10-fold (Fig. 4 and supplemental File 1). These
genes may include the direct and indirect Myb target genes and
the genes that are regulated as a function of the differentiation
process. We then prepared RNAs from the IL-6-treated M1
cells, which constitutively expressed either c-Myb or both c-
Myb and p53, and subjected them to micro-array analysis. The
results indicate that 628 genes are down-regulated more than
2-fold in the p53-expressing cells, compared with cells lacking
p53 (Fig. 4 and supplemental File 2). Comparison of the 122
genes that were induced more than 10-fold in the c-Myb-ex-
pressing cells with the 628 genes that were down-regulated by
p53 expression identified 28 common genes (Fig. 4, left), indi-
cating that about 23% of the genes, which were induced by
c-Myb expression, are negatively regulated by p53. These 28
genes include 9 genes that encode proteins of known function,
such as granzyme E, and 19 genes that encode proteins of
unknown function (Fig. 4, right, and supplemental File 3). The
degree of down-regulation of these genes by p53 expression
(2.0–3.7-fold) is relatively low compared with the level of up-
regulation by c-Myb expression (10.6–147-fold). This may be
due to the relatively low level of p53 expression in the M1 cells
(high levels of p53 induced a rapid apoptosis; data not shown).
Comparison of the 3,157 genes, which were down-regulated
40% or more by p53 expression, with the 533 genes, which were
up-regulated more than 5-fold by constitutive expression of
c-Myb, identified 285 genes (53%) in common (data not shown).
These include c-myc, which was up-regulated 34.0-fold by con-
stitutive expression of c-Myb and down-regulated 1.8-fold by
p53 expression. Thus, a considerable number of c-Myb target
genes are negatively regulated by p53.
p53 Recruits mSin3A to c-Myb—To investigate the mecha-
nism by which p53 inhibits c-Myb-induced trans-activation, we
first examined the effect of p53 on the DNA binding capacity of
c-Myb (Fig. 5A). In gel mobility-shift assays, the recombinant
R123 protein, which contained only the DBD of c-Myb, bound to
the Myb binding site-I probe and generated a retarded band.
Addition of GST-p53 to this reaction gave rise to an additional
band, whereas GST-p53 alone did not generate a retarded
band. An anti-Myb antibody super-shifted both of these bands,
whereas anti-p53 antibody only slightly diminished the band
generated by addition of GST-p53, possibly due to the low
affinity of the p53 antibody to p53 in the complex. Addition of
FIG. 5. p53 recruits mSin3A to c-Myb. A, p53 does not block the DNA binding of c-Myb. Gel retardation assays were performed using a probe
containing the Myb-binding site, the recombinant Myb containing only three repeats of its DBD (R123), and the GST-p53 protein. In some lanes,
anti-c-Myb or anti-p53 antibodies were added. B, p53 and mSin3A additionally inhibit the c-Myb-dependent transcription. 293T cells were
transfected with the 6MBS-Luci reporter with () or without () the c-Myb expression plasmid and increasing amounts of the p53 and mSin3A
expression plasmids. Luciferase activity was then measured. The average of three experiments is shown. C, two-step co-immunoprecipitation of
the complex containing c-Myb, p53, and endogenous mSin3A. Lysates from 293T cells transfected with plasmids to express FLAG-c-Myb or
untagged c-Myb and p53, were first precipitated with anti-FLAG antibody, eluted with FLAG peptide, and analyzed by Western blotting with the
antibodies indicated on the left. The eluates were then immunoprecipitated with the anti-p53 antibody or a control IgG, followed by Western
blotting. D, ChIP assays. Soluble chromatin was prepared from the M1 cells that constitutively express c-Myb and p53ts and immunoprecipitated
with the antibodies indicated above each lane. In the central three lanes, to activate p53ts, the cells were cultivated for 2 h at 32 °C just before lysate
preparation. The final DNA extractions were amplified using pairs of primers that cover the region of the c-myc promoter. The relative densities
of bands are indicated below.
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control IgG did not affect either of these bands. These results
indicate that p53 interacts with c-Myb bound to the Myb bind-
ing site-I DNA, generating a p53-Myb-DNA complex and that
p53 does not inhibit the DNA binding of c-Myb.
It has been previously reported that p53 represses transcrip-
tion by recruiting the corepressor mSin3A (13). In addition, we
recently found that mSin3A also directly binds to c-Myb and
inhibits c-Myb-induced trans-activation (32). Therefore, we
speculated that p53 may suppress c-Myb-dependent trans-ac-
tivation by recruiting mSin3A to c-Myb. To investigate this
possibility, we first examined the effect of p53 and mSin3A on
c-Myb-dependent trans-activation. Co-expression of both p53
and mSin3A resulted in an additive effect on suppression of the
c-Myb-dependent transcription from the Myb site containing
promoter (Fig. 5B), suggesting that p53 and mSin3A act to-
gether to suppress c-Myb-dependent transcription.
To examine whether c-Myb, p53, and mSin3A form a com-
plex, a two-step co-immunoprecipitation was performed (Fig.
5C). 293T cells were co-transfected with expression plasmids
for FLAG-tagged or untagged c-Myb, and p53. Cell lysates were
prepared and first immunoprecipitated with an anti-FLAG an-
tibody. This immunocomplex was eluted with a FLAG peptide
and found to contain p53, endogenous mSin3A, and FLAG-c-
Myb. The FLAG-peptide eluates were then immunoprecipi-
tated with anti-p53 or control IgG. The anti-p53 immunocom-
plex contained endogenous mSin3A, but the IgG complex did
not. Thus, c-Myb, p53, and mSin3A can form a complex.
We then examined the p53-dependent recruitment of
mSin3A to the c-myc gene promoter by chromatin immunopre-
cipitation (ChIP) assays. We recently demonstrated that c-Myb
binds to the c-myc promoter region using ChIP assays (32). We
used M1 cell clones that constitutively express c-Myb and
p53ts. Anti-p53 and anti-mSin3A antibodies precipitated the
mouse c-myc promoter 343-bp DNA fragment (782 to
11249), which contains two Myb-binding sites (40), from cells
cultivated at 37 °C (Fig. 5D, left three lanes). Other regions of
c-myc DNA, which contained no Myb-binding sites (705 to
945 and 5 to 235) were not precipitated (data not shown).
These results indicate that some amount of p53, which does not
have a functional protein conformation, and mSin3A proteins
bind to the c-myc promoter region via c-Myb. Activation of p53
by cultivation of cells at 32 °C increased the amounts of c-myc
promoter fragment precipitated by anti-p53 and anti-mSin3A
antibodies (Fig. 5D, middle three lanes), suggesting that the
number of mSin3A molecules that bound to the c-myc promoter
increased in p53-overexpressing M1 cells. Thus, p53 recruits
mSin3A to the c-myc promoter. Because the c-myc promoter
does not contain the consensus p53-binding sequence, p53 is
likely to bind to the c-myc promoter via c-Myb.
Sumoylation of p53 Suppresses the Interaction with c-Myb—
The C-terminal 78-amino acid region of p53, which contains the
tetramerization domain directly interacts with c-Myb (Fig. 1B).
Interestingly, lysine 386 in this region is known to be sumoy-
lated (41, 42). To examine whether the sumoylation of p53 at
K386 affects its interaction with c-Myb, we used sumoylated
GST-p53 for in vitro binding assays. Bacterially expressed
GST-p53 was bound to glutathione beads and incubated with
SUMO-1 or SUMO-2 and E1 and E2 enzymes. SDS-PAGE
analysis indicated that about 90% of GST-p53 was sumoylated
(Fig. 6A). These sumoylated GST-p53 and the control non-
sumoylated GST-p53 proteins were used for pull-down assays
with in vitro-translated c-Myb and mSin3A. Binding efficiency
of c-Myb and mSin3A to the sumoylated GST-p53 was about
half that of control GST-p53 (Fig. 6B). Thus, sumoylation of p53
suppresses the ability of p53 to inhibit c-Myb-dependent
trans-activation.
DISCUSSION
The mechanism by which p53-dependent repression of tran-
scription is translated into cell cycle arrest or induction of
apoptosis by p53 is not well understood. The present study
indicates that p53 inhibits a group of c-Myb target genes by
FIG. 7. Schematic representation of
the negative regulation of c-Myb-in-
duced trans-activation by p53.
FIG. 6. Sumoylation of p53 suppresses the interaction with c-Myb. A, preparation of recombinant sumoylated GST-p53. GST-p53 was
sumoylated in vitro and analyzed by SDS-PAGE followed by Coomassie Blue staining. B, GST pull-down assays. In vitro translated c-Myb or
mSin3A were mixed with 5 g of GST, GST-p53, or sumoylated GST-p53 beads, and bound proteins were analyzed by SDS-PAGE, followed by
autoradiography. C, GST pull-down assays were performed using different amounts of GST fusion protein, and the binding efficiency is indicated
by the bar graph.
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recruiting mSin3A (Fig. 7). c-Myb induces the expression of
various genes that are involved in G1/S progression and sup-
pression of apoptosis, and the induction of these target genes
mediates the capacity of c-Myb to induce cell cycle progression
and to protect cells against apoptosis. We have identified 28
genes that are up-regulated more than 10-fold by c-Myb expres-
sion and down-regulated more than 2-fold by p53. These in-
clude Flt3 (fms-like tyrosine kinase 3), which is required for
proliferation of immature hematopoietic cells. These results
suggest that p53 suppresses multiple c-Myb target genes. We
previously showed that p53 induces c-Myb degradation by in-
ducing the ubiquitin E3 ligase Siah-1, which directly binds to
c-Myb (33). Therefore, p53 negatively regulates c-Myb activity
by two mechanisms; an inhibition of c-Myb-dependent trans-
activation by direct binding and by Siah-1-mediated degrada-
tion of c-Myb. The former may act immediately after p53 in-
duction, whereas the latter may function in the later stage
after Siah-1 induction. In leukemia, colon cancers, and breast
cancers where Myb is expressed, p53 is frequently mutated. In
addition, it was reported that loss of p53 allows the immortal-
ization of hematopoietic cells by themyc gene, which is a direct
target of Myb (43). Together with these reports, our results
may support the idea that loss of p53 function in these cases
contributes to transformation by up-regulating Myb activity.
Because p53 is known to interact with various transcription
factors, p53 may repress transcription of additional cell-cycle or
apoptosis-related genes by mechanisms similar to those iden-
tified here.
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SUPPLEMENTARY FIGURES LEGENDS 
Supplementary Fig. 1. GST pull-down assays using GST-p53 and in vitro-translated 
c-Myb. A, The various c-Myb constructs used are indicated, and the results of binding assays 
are summarized on the right. B, Binding of various forms of in vitro translated c-Myb to 
GST-p53 resin was analyzed by SDS-PAGE followed by autoradiography. 
Supplementary Fig. 2. The c-Myb-interacting region of p53. (Upper) The domain structure 
of p53, and various forms of p53 used, are shown. The results of binding assays are 
summarized on the right. (Lower) Binding of various forms of in vitro translated p53 to 
GST-c-Myb was examined. 
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